Table 1.

Clinical and in vitro characteristics of the clinical isolates and transformants of KP76 and EA76

Isolatea	Sex/ageb	Originc	PFGE	MLST	KPC/ rmtB	MIC (mg/L)d
						IP	MP	ETP	PP	PTC	CT	TZ	PM	AT	GM	AK	CL	CO	TGC	CTL	TZL
KP76	M/41	Stool	1	11	+/+	32	32	32	≥256	≥256	≥32	≥32	16	≥256	≥256	≥256	≥32	0.38	1	≥1	≥4
KP76-T			UDe	UD	+/+	1.5	0.75	2	≥256	128	≥32	≥32	3	≥256	≥256	≥256	0.012	0.13	0.75	≥1	≥4
EA76	M/41	Blood	UD	UD	+/+	16	16	32	≥256	≥256	≥32	≥32	16	≥256	≥256	≥256	≥32	1.5	1	≥1	≥4
EA76-T			UD	UD	+/+	1.5	1	32	≥256	≥256	≥32	≥32	8	≥256	≥256	≥256	0.012	0.13	0.75	≥1	≥4
E. coli DH5α			UD	UD	UD	0.125	0.016	0.125	2	2	0.125	0.25	0.02	0.02	0.38	0.75	0.012	0.02	0.19	0.13	0.25
KP31	M/25	CSF	1	11	+/+	128	64	128	≥512	≥512	≥512	256	512	≥512	≥512	≥512	≥32	1	2	UD	UD
KP34	F/47	URT	1	11	+/+	128	64	128	≥512	≥512	≥512	512	256	≥512	≥512	≥512	≥32	1	2	UD	UD
KP35	M/82	LRT	1	11	+/+	128	64	128	≥512	≥512	≥512	1024	256	≥512	≥512	≥512	≥32	0.5	2	UD	UD
KP45	F/67	LRT	2	494	−/−	4	2	4	512	512	512	128	64	≥512	8	2	16	1	2	UD	UD
KP48	M/65	LRT	1	11	+/+	128	64	128	≥512	≥512	≥512	256	256	≥512	512	≥512	≥32	0.5	0.5	UD	UD
KP54	M/72	Blood	3	23	−/−	64	64	128	≥512	512	128	256	128	≥512	4	2	1	1	1	UD	UD
KP86	M/61	LRT	1	11	+/−	256	128	256	≥512	≥512	128	128	128	≥512	0.5	8	1	1	2	UD	UD
KP98	F/46	LRT	1	11	+/−	256	64	256	≥512	512	256	512	128	≥512	2	1	0.5	1	2	UD	UD
KP104	M/46	LRT	1	11	+/+	128	64	128	≥512	≥512	≥512	128	128	≥512	≥512	≥512	≥32	2	2	UD	UD
KP111	M/62	Secretion	1	11	+/+	128	64	128	≥512	≥512	≥512	256	256	≥512	≥512	≥512	≥32	1	2	UD	UD
KP215	M/43	LRT	1	11	+/+	256	64	128	≥512	≥512	128	128	64	≥512	512	≥512	≥32	1	2	UD	UD

^aKP76-T, E. coli transformant of KP76; KP76-T, E. coli transformant of EA76

^bM, male; F, female; age given in years

^cCSF, cerebrospinal fluid; URT, upper respiratory tract; LRT, lower respiratory tract

^dIP, imipenem; MP, meropenem; ETP, ertapenem; PP, piperacillin; PTC, piperacillin–tazobactam; CT, cefotaxime; TZ, ceftazidime; PM, cefepime; AT, aztreonam; GM, gentamicin; AK, amikacin; CL, ciprofloxacin; CO, colistin; TGC, tigecycline; CTL, cefotaxime–clavulanic acid; TZL, ceftazidime-clavulanic acid

^eUD, undetermined